Large-scale phenotyping efforts have demonstrated that approximately 25-30% of mouse gene knockouts cause intrauterine lethality. Analysis of these mutants has largely focused on the embryo and not the placenta, despite the crucial role of this extraembryonic organ for developmental progression. Here we screened 103 embryonic lethal and sub-viable mouse knockout lines from the Deciphering the Mechanisms of Developmental Disorders program for placental phenotypes. We found that 68% of knockout lines that are lethal at or after mid-gestation exhibited placental dysmorphologies. Early lethality (embryonic days 9.5-14.5) is almost always associated with severe placental malformations. Placental defects correlate strongly with abnormal brain, heart and vascular development. Analysis of mutant trophoblast stem cells and conditional knockouts suggests that a considerable number of factors that cause embryonic lethality when ablated have primary gene function in trophoblast cells. Our data highlight the hugely underappreciated importance of placental defects in contributing to abnormal embryo development and suggest key molecular nodes that govern placenta formation.
Placentation defects are highly prevalent in embryonic lethal mouse mutants Vicente Perez-Garcia 1,2 *, Elena Fineberg 1,2 *, robert Wilson 3 , alexander murray 1,2 , cecilia icoresi mazzeo 4 , catherine Tudor 4 , arnold Sienerth 1,2 , Jacqueline K. White 4 , Elizabeth Tuck 4 , Edward J. ryder 4 1, 2 Systematic identification of the genes required for normal embryogenesis is essential if we are to successfully unravel the molecular framework that underpins embryo development. Such knowledge will help to identify genetic causes of developmental abnormalities that manifest during pregnancy or at birth, and comprise a considerable health burden. Large-scale phenotyping efforts have consistently found that 25-30% of mouse gene knockouts result in non-viable offspring [1] [2] [3] [4] [5] . In almost all studies of developmentally critical genes, research has focused on the impact of the mutation on the embryo. By contrast, little attention has been paid to the possible effects of these mutations on extraembryonic tissues, almost certainly resulting in underrepresentation of placental phenotypes in public databases. The Mouse Genome Informatics (MGI) database, for example, shows extraembryonic defects in only 10% of embryonic-lethal strains. Gaining a more accurate view of the actual frequency of placental abnormalities is crucially important for our understanding of the contribution of this vital organ to the aetiology of developmental defects and congenital abnormalities 6 .
Several groundbreaking studies have highlighted the essential role of extraembryonic tissues for normal development and long-term health. Placental insufficiency results in intrauterine growth retardation and, as a consequence, can cause fetal programming effects that predispose to later-onset disease 7, 8 . Moreover, tetraploid complementation 9 or conditional gene ablation experiments have identified embryoniclethal phenotypes in which normal development can be entirely rescued solely by providing the embryo with a wild-type placenta [10] [11] [12] [13] [14] [15] .
However, systematic efforts to discover the genes required for normal placental development are still missing. The Deciphering the Mechanisms of Developmental Disorders (DMDD; https://dmdd.org.uk) consortium 16 is one of several ongoing programmes dedicated to identifying and characterizing embryonic-lethal genes in the mouse. In addition to detailed phenotypic assessment of structural abnormalities in mutant embryos, the DMDD project also investigates the effect of each mutation on placental development. Here we report the analysis of placental morphology for 103 such lines. Our results reveal a markedly higher rate of placental phenotypes than had been previously appreciated, and a striking association of placental defects with specific abnormalities in the embryo itself. Our study identifies the placenta as a pivotal target organ for the effects of gene mutations that contribute to developmental demise.
Placental defects in embryonic-lethal mouse lines
We analysed 103 mouse knockout lines that fail to produce mutant offspring at the expected Mendelian frequency at postnatal day (P)14, but yielded mutant embryos at either embryonic day (E)14.5 or E9. 5 . Lines for which mutant conceptuses could not be recovered at E9.5 were not included in this screen. Of the 103 lines analysed, 82 were classified as P14 lethal, as no mutant offspring were recovered at that stage. The remaining 21 lines were termed sub-viable, with mutant pups constituting 13% or less of all offspring obtained, a proportion significantly below the 25% expected from heterozygous crosses ( Fig. 1a , Supplementary Table 1 ). Similar criteria were applied to sub-categorise the P14 lethal group further according to viability at E14.5 (Fig. 1a ).
Placentas of all lines were subjected to histopathological analysis at E9.5, E14.5 or both (Supplementary Table 1 ). As expected, less than 1% of wild-type placentas showed an abnormal phenotype. By contrast, in mutant placentas we detected dysmorphologies in 56 out of 82 (68%) of P14 lethal strains (Fig. 1b) . Even when the P14 sub-viable lines were included, the placental phenotype rate was still 59%, a far higher frequency than the approximately 10% annotated in the MGI database ( Fig. 1b ). All genes associated with placental abnormalities in mutants were expressed in the trophoblast lineage of this organ (Extended Data Fig. 1a ), lending support to the notion that they contribute directly to placental growth or function.
We also assessed the conceptuses for yolk sac defects, an extraembryonic structure that is especially important for nutrient provision during the first half of gestation, before formation of the functional placenta at E9.5 ( Supplementary Table 1 ). Because the yolk sac was routinely used for genotyping, it proved only possible to analyse this tissue in 66 lines. Among these, an abnormal yolk sac morphology was detected in 11% (7 out of 66) of cases, compared to approximately 6% annotated among prenatal lethals in the MGI database. Notably, all seven affected lines fell within the E9.5-E14.5 lethal group (7 out of 24 = 29%; Fig. 1c ). Thus, although yolk sac defects that affect its structure or haemato poietic function may contribute to the lethality of some of these early lethal strains, they occur at a much lower frequency than placental abnormalities.
When scoring the occurrence of placental defects as a function of developmental stage, we found that almost every line that died before E14.5 exhibited placental abnormalities (40 out of 41; Fig. 1d , Extended Data Fig. 1b ), compared to only 35% of lines that were viable beyond E14.5 (12 out of 34) ( Fig. 1d , Supplementary Table 1 ). These findings demonstrate that mutations resulting in embryonic lethality between E9.5 and E14.5 are almost certainly associated with a defective placenta.
In line with the placenta being the essential nutrient-supplying organ from mid-gestation onwards, we also found that mutant E14.5 embryos in strains exhibiting a placental phenotype were shifted to a younger developmental stage compared to those in which placental development was normal 17 (Fig. 1e , Extended Data Fig. 1c ).
Categories of placental defects
To categorise the different types of defect, we examined the three main layers of the mature placenta: the labyrinth, which constitutes the main nutrient and gas-exchange surface; the junctional zone, which consists of spongiotrophoblast, glycogen cells and different giant cell subtypes; and the maternally derived decidua (Fig. 2 , Extended Data Fig. 2a ).
Haematoxylin and eosin histology (Extended Data Fig. 2b , c) was complemented with three histological staining methods to accurately classify the cellular and tissue composition defects in abnormal placentas using a series of phenotype criteria ( Fig. 2a, b ). At E9.5, a frequently detected malformation affected the invagination of allantoic blood vessels into the chorionic ectoderm, a process crucial for the development of the labyrinth that will almost certainly result in developmental arrest ( Fig. 2a , c, Extended Data Fig. 2b ). At E14.5, by far the most prevalent abnormalities were defects in the growth and intricate organization of the fetal and maternal blood conduits within the labyrinth layer ( Fig. 2b, d , Extended Data Fig. 2c ). Because these abnormalities diminish the surface area available for nutrient transport, they will compromise fetal growth and survival.
Collectively, these histological characterizations of more than 300 mutant placentas provide a vast resource for the research community (all data are available at https://dmdd.org.uk).
Critical nodes in placental development
We next examined whether the identity of genes associated with placental defects suggested specific molecular pathways that may be pivotal for the formation or function of this organ. For genes that affect placental morphology at E9.5 in mutants, this network analysis highlighted several functional gene clusters that centred around L3mbtl2, Bap1 and Arhgef7 ( Fig. 2e , Extended Data Fig. 1d ). Similarly, several factors identified in the E14.5 analysis formed specific molecular nodes, for example, around Traf2, Nek9 and Rpgrip1l (Extended Data Fig. 1d ). Although relatively few genes have been analysed for defects in extraembryonic tissues in the literature, it is obvious that a large fraction of network components identified in our analyses have been associated with embryonic phenotypes. It therefore seems highly likely that mutants for many of these functionally connected genes will also exhibit placental abnormalities.
Embryo and placenta defects are linked
Because the DMDD program scores both embryonic and placental defects, it provides a unique opportunity to assess co-associations between specific phenotypes 18, 19 . Importantly, DMDD phenotype calls are based on precise embryo sub-staging, and the analysis therefore excludes any apparent phenotypes that simply reflect the developmental delay prevalent among embryos with placental defects. Nevertheless, mutant mouse lines that exhibit placental abnormalities were enriched for specific E14.5 embryo phenotypes that were distinct from those with normal placentas (Extended Data Fig. 3a ).
Embryo phenotype categories that show significant statistical correlation with placental defects included abnormalities in the heart, brain and vascular system ( Table 2 ). In particular, this affected anomalies in forebrain development, heart chamber and septum morphology, subcutaneous oedema, and overall artery or vein topology ( Fig. 3b-d , Extended Data Fig. 4c, d) . These phenotype co-associations suggest co-regulatory or inter-dependent mechanisms during the development of particular organ systems, notably between the placenta and morphogenesis of the brain, heart and vascular system.
Trophoblast-specific gene functions
Because the placenta comprises cell types of distinct lineage origins, a placental phenotype may be caused by trophoblast-intrinsic and/or extraembryonic mesoderm-derived endothelial cell defects. To determine trophoblast-specific functions of genes identified as important for placental development, we used CRISPR-Cas9-mediated ablation in trophoblast stem cells (TSCs) [20] [21] [22] (Extended Data Fig. 5 ). We chose three genes for this analysis that caused lethality around E9.5-E10.5 when ablated: the tumour suppressor Bap1, the cell polarity complex member Crb2 and the nucleotide binding protein-like factor Nubpl (Extended Data Fig. 6 ). Nubpl-mutant TSCs exhibited a decreased stem-cell potential, as evidenced by lower expression levels of Cdx2, Esrrb and Elf5, which may explain the marked reduction in the size of the trophoblast compartment in Nubpl −/− placentas. Moreover, severely impaired upregulation of Gcm1 (an early marker of syncytializing trophoblast) and lower expression levels of Syna and, to a lesser extent, Synb showed that differentiation towards the syncytiotrophoblast lineage was inhibited in the absence of Nubpl (Fig. 4a , Extended Data Fig. 7a ). We also detected a prominent phenotype in Bap1-deficient TSCs, as they displayed increased expression of the key stem-cell markers Cdx2 and Esrrb when grown under self-renewal conditions. When triggered to differentiate, Bap1 −/− TSCs failed to upregulate markers of syncytiotrophoblast, sinusoidal trophoblast giant cells and glycogen cells ( Fig. 4b , Extended Data Fig. 7b ). These TSC differentiation defects may well contribute to the labyrinth formation phenotype evident in both Nubpl and Bap1 mutants. By contrast, Crb2-null TSCs were indistinguishable from wild-type (empty vector) controls (Extended Data Fig. 7c ).
Lineage origins of placental defects
To gain further insights into trophoblast-intrinsic versus embryonic lineage-induced effects, we chose the same three genes that we studied in TSCs for conditional gene ablation in vivo. Thus, we used the Sox2cre transgene to delete the function of these genes in the embryo, while leaving expression intact in the trophoblast-derived cells of the placenta and the visceral yolk sac endoderm 23 (Fig. 5a ). Nek9 Nubpl-null embryos associated with a heterozygous placenta were considerably more advanced in development than their complete knockout counterparts at E9.5 and could still be recovered up to E11.5, a stage when the complete knockout was already resorbed (Fig. 5a , Extended Data Fig. 8a ). Histological examination of the E9.5 and E11.5 placentas showed that the trophoblast expansion, syncytiotrophoblast differentiation and labyrinth vascularization defects were seemingly fully rescued in the conditional knockouts ( Fig. 5b , Extended Data Fig. 8b ). This rescue was also suggested by the transcriptome-wide similarity between conditional knockout and wild-type or heterozygous control placentas (Extended Data Fig. 9a ). Thus, although the conditional Nubpl mutation is still lethal beyond E11.5 owing to an essential role of this gene in the embryo proper, a functional trophoblast lineage rescues the placental phenotype and the resulting early mid-gestation embryonic lethality.
For Bap1, syncytiotrophoblast formation was partially restored in conditional knockout placentas. Furthermore, global expression profiles of Bap1 conditional knockout placentas were more similar to controls than to knockouts (Extended Data Fig. 9a, b ). However, placental vascularization remained underdeveloped and the conceptuses still died at mid-gestation (Extended Data Fig. 9b ). This indicates an essential additional function of Bap1 in the extraembryonic mesoderm compartment that prevents placental labyrinth formation and also results in a yolk sac defect in knockouts and conditional knockouts (Extended Data Fig. 10a ). Similarly, Crb2-null embryos could not be rescued by a genetically functional trophoblast lineage (Extended Data Fig. 10b ), a result consistent with the lack of phenotype in mutant TSCs. Because the yolk sac phenotype also remained unchanged in conditional knockouts, it can be concluded that the chorio-allantoic placentation defect is due to the crucial role of Crb2 in mesoderm development 24 .
In summary, in vitro and in vivo analysis of three genes whose mutation causes mid-gestational lethality identified two factors (Nubpl and Bap1) with important roles in the proper expansion and differentiation capacity of trophoblast cells. One of these (Nubpl) is indeed causative of the embryonic lethal phenotype at E9.5.
Discussion
Systematic mouse knockout phenotyping efforts undertaken so far have excluded the analysis of extraembryonic tissues, most notably the placenta [3] [4] [5] 25 . Ignoring placental defects as a major contributory factor to fetal demise has previously led to several prominent examples of misannotation of gene function, such as for the tumour suppressor Rb1 and the oncogene Myc [26] [27] [28] [29] . In both cases, subsequent studies have revealed that restoring gene function to the trophoblast lineage could largely rescue the embryonic defects observed 30, 31 . Here, we report a systematic effort to assess the prevalence of placental abnormalities in P14 lethal or sub-viable mouse mutants that survive to at least mid-gestation.
We find a remarkably high percentage of placental abnormalities among these lines, with two-thirds of all P14 lethal strains exhibiting obvious defects. In particular, knockouts that result in mid-gestational Ssr2
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Forebrain lethality are almost certainly associated with an abnormal placenta, underpinning the notion that defects in placentation create a bottleneck for developmental progression past mid-gestation 32 . This frequency of placental defects illustrates the hugely underestimated effect of gene mutations on extraembryonic tissues. Given that approximately 25-30% of all mutations cause embryonic lethality, our data suggest that a placental phenotype has gone unnoticed and unreported in hundreds if not thousands of mutant strains. Many of the genes associated with placental defects in our screen are part of specific functional hubs, such as the L3mbtl2 Polycomb group complex and the tumour necrosis factor-receptor associated factor (Traf2) network, which seem to be of major importance for placental development. Identification of such molecular nodes holds great promise as a way of gaining insights into the causes of placentation defects in humans. Consistent with this, at least three of the genes we assessed, TRAF2, PSPH and BAP1 (through its established interaction with ASXL3) have been implicated in the pathophysiology of human pregnancy disorders, many of which have their origin in defective placentation [33] [34] [35] [36] .
A unique feature of our study is the integrated analysis of both embryo and placenta. This has revealed important co-associations between the occurrence of a placental phenotype and particular defects within the embryo itself, notably affecting neurodevelopment, the heart and the overall vascular system. A placenta-heart axis has been recognized before [37] [38] [39] [40] ; however, we can now identify highly specific pathologies such as a double outlet right ventricle and ventricular septal defects that strongly correlate with the presence of an abnormal placenta. Effects of placental insufficiency on brain development have also been reported 31, 41, 42 ; our large-scale screen provides strong correlative evidence to support this developmental co-relationship. By contrast, a systematic effect of the placenta on vascular development, beyond overall haemodynamics 43 , has not previously been recognized. The importance of our findings may therefore extend not only through the immediate gestational period, but also into postnatal life, and may help to explain how placental insufficiency can have long-lasting consequences on cardiovascular disease risk, outweighing other behavioural factors 44 .
Taken together, we demonstrate that placental malformations are far more common than previously thought in embryonic-lethal mutations and co-occur specifically with heart, brain and vascular network defects. Our data highlight the importance of including extraembryonic tissues in studies investigating the genetic basis of congenital abnormalities.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Mouse lines. Most mouse lines were generated using the EUCOMM/KOMP knockout first conditional-ready targeted ES cell resource (http://www.mouse phenotype.org/about-ikmc/eucomm-proram/eucomm-targeting-strategies; targeted trap 'tm1a' allele and null 'tm1b' allele). A few lines were generated by CRISPR-Cas9-mediated gene deletion ('em1' allele). All lines were produced and maintained on a C57BL/6N genetic background at the Wellcome Trust Sanger Institute (http:// www.mousephenotype.org/) as part of the DMDD project 16 . Use of all animals was in accordance with UK Home Office regulations, the UK Animals (Scientific Procedures) Act of 1986 and approved by the Wellcome Trust Sanger Institute's Animal Welfare and Ethical Review Body. Gene knockout lines were designated lethal if no homozygous mutants were present among a minimum of 28 pups at P14 and sub-viable if their proportion fell on or below 13% of total offspring from hetero zygous intercrosses 5 . Corresponding cut-off criteria applied to the designation of sub-viability at E14.5. These 'DMDD lines' were assessed at embryonic days E14.5 and/or E9.5, counting the day of the vaginal plug as E0.5. Embryos, placentas and yolk sacs were collected; embryos were processed for HREM imaging 19 , placentas were fixed in 4% paraformaldehyde (PFA) and yolk sacs were used for genotyping.
For conditional gene ablation in the embryo proper ('placental rescue'), lines were mated to Flp expressors to generate conditional 'tm1c' alleles (http:// www.mousephenotype.org/about-ikmc/eucomm-program/eucomm-targetingstrategies), and then crossed with Sox2-cre transgenic mice 23 . Informative crosses were set up between females carrying at least one conditional allele at the locus of interest and heterozygous males that additionally carried the Sox2-cre transgene. Embryos and placentas were collected as before; genotyping was performed on embryonic tail biopsies. Histology. For histological analysis, at least three mutant and three wild-type placentas from at least two independent litters (with pairs of mutant and wild-type placentas recovered from the same litter if possible) were processed for routine paraffin histology and embedded side-by-side for each strain. No statistical methods were used to predetermine sample size. Placentas of male and female conceptuses were analysed wherever possible. No other randomization is applicable for this study. In all cases, tissue appearance and cellular architecture of the placentas analysed confirmed they were in viable condition even if the associated embryo had been designated as dead or dying. Consecutive 7-μm sections were produced, and alternate sections mounted. A series of sections per block was processed for haematoxylin and eosin (H&E) staining, using a standard protocol (https://dmdd.org.uk/ placental-analysis-protocols/). Sections through the sagittal midline were chosen for imaging, indicated at E9.5 by the remnant of the uterine lumen and at E14.5 by the site of insertion of the umbilical cord. Slides were scanned on a Hamamatsu slide scanner and images deposited at https://dmdd.org.uk. Phenotypes of placentas were assessed for each strain, blinded for strain viability scores, and recorded by at least two independent investigators. In cases in which all three mutant placentas exhibited a particular abnormality, that defect was scored as a phenotype. In cases in which a defect was unambiguously detected only in two of the initial three placentas analysed, an additional two or three mutant placentas were added to confirm the call. Overall, a phenotype was scored when at least 67% of mutant placentas exhibited that particular abnormality. Criteria for assessing yolk sac morphology encompassed apposition of the visceral yolk sac endoderm and mesoderm layers, and the appearance of blood islands. Immunostaining and in situ hybridization. To gain a more precise view of the structural defects in mutant placentas, mutant placentas from all lines were stained for E-cadherin (Cdh1) to demarcate the labyrinthine syncytiotrophoblast (as well as parietal giant cells at E9.5) and with isolectin BSI-B4 to outline labyrinthine trophoblast and decidua. In situ hybridization for Tpbpa was used to label the spongiotrophoblast and glycogen cells.
For immunostaining, sections were deparaffinised in xylene and processed through an ethanol series to PBS. Antigen retrieval was performed by boiling in 1 mM EDTA pH 7.2, 0.05% Tween-20 or in 10 mM Na-citrate pH 6.0 buffer followed by blocking in PBS, 0.5% BSA, 0.1% Tween-20. Antibodies used were anti-Cdh1 (1:100; BD Biosciences 610181), anti-laminin (1:100; Sigma L9393), anti-MCT4 (1:100; Merck Millipore AB3314P) and biotin-conjugated isolectin from Bandeiraea simplicifolia BSI-B4 (1:100; Sigma L2140). Primary antibodies were detected with appropriate fluorescence or horseradish peroxidase-conjugated secondary antibodies; BSI-B4 was detected with horseradish peroxidase-conjugated streptavidin. Nuclei were counterstained with haematoxylin or DAPI. In situ hybridization for Tpbpa was performed using a standard protocol 45 . Phenotype data analysis. All genes associated with a placental phenotype in mutant mouse lines were selected for interaction network analysis using esyN (http://www.esyn.org), displaying genetic and physical interactions. Expression data for all genes assessed in mouse mutants was obtained by meta-analysis of published RNA sequencing (RNA-seq) datasets 22 . For test-ing for co-associations between embryonic and placental defects, two separate analyses were performed. First, we examined the phenotypes of homozygous mutant embryos in which the placentas have been scored for abnormalities (122 embryos), and second, we analysed all homozygous mutant embryos scored for mutant phenotypes (241 embryos) according to placental abnormality observed within the line, which builds on our observation that placental abnormalities were fully penetrant in almost every line. The phenotypes scored in homozygous mutant embryos were summarized into broader phenotype categories within the Mammalian Phenotype Ontology by mapping the phenotype terms recorded onto the DMDD intermediate slim as described 46 .
Statistical analysis used Fisher's exact test to assess for an association or increase in abnormality rate of the phenotypes when placentas were scored as abnormal. An orthogonal potential alpha-star filter was used before the statistical testing to reduce the multiple testing burden as recently described 18 . To assess the biological effect of placental abnormalities on the abnormality rate of mutant phenotypes, we followed the previously described procedure 18 of determining the difference in two binomial proportions and calculating the 95% confidence interval using Newcombe's recommended method 10 using the ci.pd function of the R Epi package. Significance was adjusted for the effects of multiple testing using the Benjamini-Hochberg procedure to control the false discovery rate at 5%. Penetrance analysis. The mammalian phenotype (MP) terms assigned during annotation of the embryos were summarized into the ontology slim categories, and the penetrance score of each slim term observed for the line calculated as previously described 46 . The phenotype data was analysed using the DMDD intermediate slim terms, and lower hierarchy slims within ontology terms abnormal brain morphology, abnormal blood vessel morphology, and abnormal heart morphology (Supplementary Table 3 ). Generation of mutant TSC lines. The wild-type blastocyst-derived TS-Rs26 TSC line (a gift from the Rossant laboratory, and tested to be mycoplasma-free) was cultured as described previously 20, 21 . Differentiation was induced by culturing in media lacking bFGF, heparin and embryonic fibroblast-conditioned medium.
For generation of CRISPR-Cas9-mediated knockout TSCs, guide RNAs (gRNAs) that result in frameshift mutations were designed using the CRISPR design tool (http://CRISPR.mit.edu) and checked for high specificity by nucleotide blast searches. gRNA sequences were cloned into the Cas9.2A-eGFP plasmid (Plasmid 48138 Addgene) and verified by sequencing. Empty vector Cas9.2A-eGFP and gene-specific gRNA plus Cas9.2A-eGFP constructs were used to generate vector control and knockout TSCs (Extended Data Fig. 6 ). Transfection was carried out with Lipofectamine 2000 (ThermoFisher Scientific 11668019) reagent according to the manufacturer's protocol. Knockout clones were confirmed by genotyping using primers spanning the deleted exon, and by reverse transcription followed by semi-quantitative PCR (RT-qPCR) with primers within, and downstream of, the deleted exon, as shown (Extended Data Fig. 6 ). Five or six independent knockout clones were analysed for each gene mutation. RT-qPCR expression analysis. Potential defects in TSC maintenance and differentiation capacity were investigated by analysing the expression levels and dynamics of trophoblast marker genes in mutant and control TSCs in stem-cell conditions and following 3 and 6 days of differentiation. Total RNA was extracted using TRI reagent (Sigma T9424), DNase-treated and 1 μg used for cDNA synthesis with RevertAid H-Minus reverse transcriptase (Thermo Scientific EP0451). Quantitative PCR was performed using SYBR Green Jump Start Taq Ready Mix (Sigma S4438) and intron-spanning primer pairs 21 ( Supplementary Table 4 ) on a Bio-Rad CFX96 or CFX384 thermocycler. Normalized expression levels are displayed as mean relative to the vector control sample; error bars indicate s.e.m. of at least three replicates. Transcriptomics analysis. Samples were lysed in TRI reagent with a 5-mm stainless steel bead (Qiagen) for 4 min at 20 Hz in a tissue lyser (Qiagen). After chloroform extraction for 30 min at room temperature, RNA was extracted from the aqueous phase using ethanol and a spin column (Qiagen RNeasy MinElute). After quantification (Qubit RNA BR) the sample was treated with DNase enzyme (Qiagen) and purified over a spin column. Adaptor indexed strand-specific RNAseq libraries were generated from 1 μg of total RNA following the dUTP method using the stranded mRNA LT sample kit (Illumina). Libraries were pooled and sequenced on Illumina HiSeq 2000 in 75-base-pair paired-end mode. FASTQ files were aligned to the GRCm38.p5 reference genome using TopHat (v2.0.13, options:-library-type fr-firststrand). Counts for genes were produced using htseqcount (v0.6.1 options:-stranded = reverse) with the Ensembl v90 annotation as a reference. The data were assessed for technical quality (GC content, insert size and gene body coverage) using QoRTs 47 and poor quality samples were removed. A variance-stabilizing transformation was applied to count data for each gene using the R package DESeq2 varianceStabilizingTransformation function 48 . Principal component analysis was performed on the transformed count data for each gene using the R prcomp function.
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Extended Data Figure 1 | Potential trophoblast gene function in mutants with placental defect. a, Expression of trophoblast control genes and the 103 DMDD genes in TSCs, TSCs differentiated for 1 or 3 days (d), and in E11.5 placentas. log 2 -transformed expression values (read counts per million) of RNA-seq data are displayed. Note that all genes associated with a placental phenotype in mutants (labelled in red font) are expressed in trophoblast. b, Frequency of placental defects annotated in mid-gestational lethal mutants (MP: 0011098) as annotated in the MGI database, compared to the findings in DMDD in which 40 out of 41 E9.5-E14.5 embryonic lethal mice were found to exhibit placental abnormalities. c, Left, volume rendered 3D model of the surface of a wild-type embryo, staged as Theiler stage (TS) 23, and coronal section through the volume rendered model. Right, equivalent images of a littermate E14.5 H13 −/− embryo, staged as TS21. Note that the models are displayed in identical resolutions. Scale bar, 1 mm. Images are representative of at least five embryos per genotype. d, Network analysis using esyN (http://www.esyn.org) for all DMDD genes identified as causing a placental phenotype in mutants. BAP1 and ASXL3 are known interactors in humans. Red circles identify genes implicated in human trophoblast-based pathologies. The analysis reveals molecular nodes that appear to be of key importance for placental development. 
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Experimental design 1. Sample size
Describe how sample size was determined.
For histological analysis, at least 3 mutant and 3 wild-type placentas recovered from at least 2 independent litters were processed for paraffin histology and embedded side-by-side in one block for each strain. In the absence of known effect sizes, no statistical method was used to pre-determine sample sizes. Phenotypes of placentas were assessed for each strain, blinded for strain viability scores, and recorded by two (H&E) or three (other types of trophoblast staining) independent investigators. In cases where all 3 mutant placentas exhibited a particular abnormality, that defect was scored as a phenotype. In cases where a defect was unambiguously detected only in 2 of the initial 3 placentas analysed, an additional 2-3 mutant placentas were added to confirm the call. Overall, a phenotype was scored when at least 67% of mutant placentas exhibited that particular abnormality. Reassuringly, the phenotypes were independently confirmed in each of the 4 staining methods (H&E, Tpbpa ISH, E-Cadherin IHC, BSI-B4 lectin staining). For mutant trophoblast stem cell lines, the number of independent clones analysed is provided for each experiment in the figures (between n=3 and n=6 independent clones for each genotype).
Data exclusions
Describe any data exclusions.
Mouse line inclusion criteria: Gene knockout lines were designated lethal if no homozygous mutants were present amongst a minimum of 28 pups at P14, and sub-viable if the proportion of mutant pups fell on or below 13% of total offspring from heterozygous intercrosses. Of these, lines that did not produce recoverable mutant conceptuses at either E9.5 or E14.5 were not analysed as part of the DMDD programme. No other mouse line or phenotype data exclusions are applicable.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
Replication was achieved insofar as the phenotype was unambiguously detected in at least 67% of mutant placentas (i.e. either 3/3 or ≥ 4/6). The phenotype was present in mutant placentas recovered from at least two independent litters. Four independent staining techniques, performed on at least 3 wild-type and 3 mutant placentas of each line in parallel, provided further independent replication and validation of phenotype calls. For trophoblast stem cells, analysis of 3-6 independently targetted knockout clones of each genotype ensured the robustness and statistical significance of data.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For each mouse line, a random selection of WT and MUT placentas from female and male conceptuses was chosen. Wherever possible, these were selected pair-wise from the same litters, and included both male and female conceptuses. No other randomization is applicable for this study.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The sample identities (wild-type or mutant) were not blinded per se, but the viability of the mouse line was (which is the important determinant of phenotype for this study). All phenotype annotations were made independently by two (H&E) or three (other types of trophoblast staining) different investigators.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used. Describe the software used to analyze the data in this study.
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Adobe Photoshop CS6 for assembly of multiple image captions; Excel for Mac 2011 for RT-qPCR analyses; R packages used are described in Methods section.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.
The majority of mouse lines were generated using the EUCOMM/KOMP knockout first conditional-ready targeted ES cell resource (http://www.mousephenotype.org/about-ikmc/ eucomm-program/eucomm-targeting-strategies) and are available through this portal. The few lines generated by Crispr-Cas9 mediated gene deletion ("em1" allele) are available through the Sanger Institute (mouseinterest@sanger.ac.uk). Mutant TS cell lines are available on request directly to the Hemberger lab (myriam.hemberger@babraham.ac.uk). There are no restrictions on the availability of any of the other materials used.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). b. Describe the method of cell line authentication used. The cell line is authenticated by morphological characteristics, differentiation characteristics and by temporally regulated expression of well-established trophoblast marker genes, that are exclusively expressed in differentiating trophoblast and not in any other cell type. c. Report whether the cell lines were tested for mycoplasma contamination.
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Yes, they were tested and proved negative.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
None of the cell lines used are listed in the ICLAC database.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide all relevant details on animals and/or animal-derived materials used in the study.
The animal species used in this study was the house mouse, Mus musculus. All knockout mouse lines were produced and maintained on the genetic background of the C57BL/6N strain at the Wellcome Trust Sanger Institute (http://www.mousephenotype.org/) as part of the DMDD project. Use of all animals was in accordance with UK Home Office regulations, the UK Animals (Scientific Procedures) Act of 1986 and approved by the Wellcome Trust Sanger Institute's Animal Welfare and Ethical Review Body. Heterozygous animals were used for intercrosses to obtain homozygous mutant offspring. Average (mean) age of females was 10.49 wks (age range 5-30 weeks) and of males 14.48 wks (age range 6-40 weeks). Offspring were analysed at P14 to determine whether mutants were obtained at ≤13%, which provided the inclusion criteria for this study. The P14 lethal or subviable lines were analysed at E14.5 and/or E9.5. Male and female conceptuses of each mutant line were analysed.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
